| Year |
Citation |
Score |
| 2025 |
Vellucci L, Barone A, Buonaguro EF, Ciccarelli M, De Simone G, Iannotta F, Matrone M, Mazza B, Vitelli R, de Bartolomeis A, Iasevoli F. Severity of autism-related symptoms in treatment-resistant schizophrenia: associations with cognitive performance, psychosocial functioning, and neurological soft signs - Clinical evidence and ROC analysis. Journal of Psychiatric Research. 185: 119-129. PMID 40179689 DOI: 10.1016/j.jpsychires.2025.03.040 |
0.699 |
|
| 2025 |
Micanti F, Caiazza C, Franzese L, D'Ambrosio M, Solini N, Iasevoli F, Fornaro M, de Bartolomeis A, Rago V. Exploring clinical phenotypes of food addiction and its distress correlates: A cross-sectional evaluation in treatment-seeking individuals with obesity. Eating Behaviors. 57: 101961. PMID 40048882 DOI: 10.1016/j.eatbeh.2025.101961 |
0.6 |
|
| 2025 |
Omlor W, Rabe F, Fuchs S, Surbeck W, Cecere G, Huang GY, Homan S, Kallen N, Georgiadis F, Spiller T, Seifritz E, Weickert T, Bruggemann J, Weickert C, Potkin S, ... ... Iasevoli F, et al. Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study. The American Journal of Psychiatry. appiajp20230806. PMID 40007253 DOI: 10.1176/appi.ajp.20230806 |
0.81 |
|
| 2025 |
Fornaro M, Caiazza C, Pistone L, Crincoli W, Pezone R, De Prisco M, Oliva V, Cilmi F, Tufano G, Miola A, Nunez N, Primavera D, Iasevoli F, Solmi M, Sambataro F, et al. Atypical depression and emotion dysregulation: Clinical and psychopathological features. Journal of Affective Disorders. 376: 410-421. PMID 39965674 DOI: 10.1016/j.jad.2025.02.034 |
0.604 |
|
| 2024 |
De Simone G, Iasevoli F, Barone A, Gaudieri V, Cuocolo A, Ciccarelli M, Pappatà S, de Bartolomeis A. Addressing brain metabolic connectivity in treatment-resistant schizophrenia: a novel graph theory-driven application of F-FDG-PET with antipsychotic dose correction. Schizophrenia (Heidelberg, Germany). 10: 116. PMID 39702476 DOI: 10.1038/s41537-024-00535-4 |
0.8 |
|
| 2024 |
Solmi M, Fornaro M, Caiolo S, Lussignoli M, Caiazza C, De Prisco M, Solini N, de Bartolomeis A, Iasevoli F, Pigato G, Del Giovane C, Cipriani A, Correll CU. Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis. Molecular Psychiatry. PMID 39695322 DOI: 10.1038/s41380-024-02733-z |
0.659 |
|
| 2024 |
Cimmino DB, Zabriskie B, Luke S, Gutman B, Isaev D, Alpert K, Glahn D, Rodrigue A, Kelly S, Pearlson G, Calhoun V, Ehrlich S, Andreassen O, Tordesillas-Gutierrez D, Crespo-Facorro B, ... ... Iasevoli F, et al. Sex differences in deep brain shape and asymmetry persist across schizophrenia and healthy individuals: A meta-analysis from the ENIGMA-Schizophrenia Working Group. Biorxiv : the Preprint Server For Biology. PMID 39484539 DOI: 10.1101/2024.10.24.619733 |
0.815 |
|
| 2024 |
Garofalo M, De Simone G, Motta Z, Nuzzo T, De Grandis E, Bruno C, Boeri S, Riccio MP, Pastore L, Bravaccio C, Iasevoli F, Salvatore F, Pollegioni L, Errico F, de Bartolomeis A, et al. Decreased free D-aspartate levels in the blood serum of patients with schizophrenia. Frontiers in Psychiatry. 15: 1408175. PMID 39050919 DOI: 10.3389/fpsyt.2024.1408175 |
0.716 |
|
| 2024 |
Fornaro M, Caiazza C, Billeci M, Berk M, Marx W, Balanzá-Martinez V, De Prisco M, Pezone R, De Simone G, Solini N, Iasevoli F, Berna F, Fond G, Boyer L, Carvalho AF, et al. Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ". Molecular Psychiatry. PMID 39026098 DOI: 10.1038/s41380-024-02645-y |
0.646 |
|
| 2024 |
Jiang Y, Luo C, Wang J, Palaniyappan L, Chang X, Xiang S, Zhang J, Duan M, Huang H, Gaser C, Nemoto K, Miura K, Hashimoto R, Westlye LT, Richard G, ... ... Iasevoli F, et al. Neurostructural subgroup in 4291 individuals with schizophrenia identified using the subtype and stage inference algorithm. Nature Communications. 15: 5996. PMID 39013848 DOI: 10.1038/s41467-024-50267-3 |
0.813 |
|
| 2024 |
Vellucci L, De Simone G, Morley-Fletcher S, Buonaguro EF, Avagliano C, Barone A, Maccari S, Iasevoli F, de Bartolomeis A. Perinatal stress modulates glutamatergic functional connectivity: A post-synaptic density immediate early gene-based network analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 111032. PMID 38762163 DOI: 10.1016/j.pnpbp.2024.111032 |
0.787 |
|
| 2024 |
D'Urso G, Magliacano A, Manzo M, Pomes MV, Iuliano C, Iasevoli F, Dell'Osso B, de Bartolomeis A. Impact of Benzodiazepines and Illness Duration on Obsessive-Compulsive Disorder during COVID-19 in Italy: Exploring Symptoms' Evolutionary Benefits. Brain Sciences. 14. PMID 38671989 DOI: 10.3390/brainsci14040338 |
0.651 |
|
| 2024 |
Fornaro M, Caiazza C, Rossano F, Cilmi F, De Prisco M, Vieta E, Thompson T, Solmi M, Carvalho AF, Iasevoli F, de Bartolomeis A. Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials: NMA driving and hypnotics. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 81: 53-63. PMID 38401406 DOI: 10.1016/j.euroneuro.2024.01.011 |
0.629 |
|
| 2024 |
Lamsma J, Raine A, Kia SM, Cahn W, Arold D, Banaj N, Barone A, Brosch K, Brouwer R, Brunetti A, Calhoun VD, Chew QH, Choi S, Chung YC, Ciccarelli M, ... ... Iasevoli F, et al. Structural brain abnormalities and aggressive behaviour in schizophrenia: Mega-analysis of data from 2095 patients and 2861 healthy controls via the ENIGMA consortium. Medrxiv : the Preprint Server For Health Sciences. PMID 38370846 DOI: 10.1101/2024.02.04.24302268 |
0.807 |
|
| 2024 |
Georgiadis F, Larivière S, Glahn D, Hong LE, Kochunov P, Mowry B, Loughland C, Pantelis C, Henskens FA, Green MJ, Cairns MJ, Michie PT, Rasser PE, Catts S, Tooney P, ... ... Iasevoli F, et al. Connectome architecture shapes large-scale cortical alterations in schizophrenia: a worldwide ENIGMA study. Molecular Psychiatry. PMID 38336840 DOI: 10.1038/s41380-024-02442-7 |
0.331 |
|
| 2024 |
Fornaro M, Caiazza C, Billeci M, Berk M, Marx W, Balanzá-Martínez V, De Prisco M, Pezone R, De Simone G, Solini N, Iasevoli F, Berna F, Fond G, Boyer L, Carvalho AF, et al. Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis. Research Square. PMID 38260297 DOI: 10.21203/rs.3.rs-3787917/v1 |
0.646 |
|
| 2023 |
Omlor W, Rabe F, Fuchs S, Cecere G, Homan S, Surbeck W, Kallen N, Georgiadis F, Spiller T, Seifritz E, Weickert T, Bruggemann J, Weickert C, Potkin S, Hashimoto R, ... ... Iasevoli F, et al. Estimating multimodal brain variability in schizophrenia spectrum disorders: A worldwide ENIGMA study. Biorxiv : the Preprint Server For Biology. PMID 37961617 DOI: 10.1101/2023.09.22.559032 |
0.815 |
|
| 2023 |
Jiang Y, Luo C, Wang J, Palaniyappan L, Chang X, Xiang S, Zhang J, Duan M, Huang H, Gaser C, Nemoto K, Miura K, Hashimoto R, Westlye LT, Richard G, ... ... Iasevoli F, et al. Two neurostructural subtypes: results of machine learning on brain images from 4,291 individuals with schizophrenia. Medrxiv : the Preprint Server For Health Sciences. PMID 37873296 DOI: 10.1101/2023.10.11.23296862 |
0.817 |
|
| 2023 |
Vellucci L, Ciccarelli M, Buonaguro EF, Fornaro M, D'Urso G, De Simone G, Iasevoli F, Barone A, de Bartolomeis A. The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia. Biomolecules. 13. PMID 37627285 DOI: 10.3390/biom13081220 |
0.844 |
|
| 2023 |
Rossano F, Caiazza C, Zotti N, Viacava L, Irano A, Solini N, Pistone L, Pezone R, Cilmi F, Ricci C, De Prisco M, Iasevoli F, Kishi T, Solmi M, de Bartolomeis A, et al. The efficacy, safety, and adverse events of azapirones in anxiety disorders: A systematic review and meta-analysis of randomized controlled trials. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 76: 23-51. PMID 37544075 DOI: 10.1016/j.euroneuro.2023.07.008 |
0.628 |
|
| 2023 |
D'Urso G, Magliacano A, Dell'Osso B, Lamberti H, Luciani A, Mariniello TS, Pomes MV, Rifici LM, Iasevoli F, de Bartolomeis A. Effects of strict COVID-19 lockdown on patients with obsessive-compulsive disorder compared to a clinical and a nonclinical sample. European Psychiatry : the Journal of the Association of European Psychiatrists. 66: e45. PMID 37258286 DOI: 10.1192/j.eurpsy.2023.2416 |
0.647 |
|
| 2023 |
D'Urso G, Pomes MV, Magliacano A, Iuliano C, Lamberti H, Manzo M, Mariniello TS, Iasevoli F, de Bartolomeis A. Depression and Anxiety Symptoms "Among the Waves" of the COVID-19 Pandemic in Obsessive Compulsive Disorder and Adjustment Disorder Patients. Healthcare (Basel, Switzerland). 11. PMID 37174803 DOI: 10.3390/healthcare11091261 |
0.642 |
|
| 2023 |
Rossano F, Caiazza C, Sobrino A, Solini N, Vellucci A, Zotti N, Fornaro M, Gillman K, Cattaneo CI, Van den Eynde V, Birkenhager TK, Ruhé HG, Stahl S, Iasevoli F, de Bartolomeis A. Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 72: 60-78. PMID 37087864 DOI: 10.1016/j.euroneuro.2023.03.012 |
0.647 |
|
| 2023 |
Iasevoli F, Avagliano C, D'Ambrosio L, Barone A, Ciccarelli M, De Simone G, Mazza B, Vellucci L, de Bartolomeis A. Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal. Biomedicines. 11. PMID 36979877 DOI: 10.3390/biomedicines11030895 |
0.82 |
|
| 2023 |
Tranfa M, Iasevoli F, Cocozza S, Ciccarelli M, Barone A, Brunetti A, de Bartolomeis A, Pontillo G. Neural substrates of verbal memory impairment in schizophrenia: A multimodal connectomics study. Human Brain Mapping. PMID 36852587 DOI: 10.1002/hbm.26248 |
0.782 |
|
| 2022 |
de Bartolomeis A, Ciccarelli M, Vellucci L, Fornaro M, Iasevoli F, Barone A. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia. Expert Opinion On Pharmacotherapy. 23: 2035-2052. PMID 36368055 DOI: 10.1080/14656566.2022.2145884 |
0.82 |
|
| 2022 |
D'Urso G, Toscano E, Barone A, Palermo M, Dell'Osso B, Di Lorenzo G, Mantovani A, Martinotti G, Fornaro M, Iasevoli F, de Bartolomeis A. Transcranial direct current stimulation for bipolar depression: systematic reviews of clinical evidence and biological underpinnings. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 121: 110672. PMID 36332699 DOI: 10.1016/j.pnpbp.2022.110672 |
0.801 |
|
| 2022 |
Somma T, Esposito F, Scala MR, Scelzo A, Baiano C, Patti S, Meglio V, Iasevoli F, Cavallo LM, Solari D, De Bartolomeis A, Cappabianca P, D'Urso G. Psychiatric Symptoms in Parkinson's Disease Patients before and One Year after Subthalamic Nucleus Deep Brain Stimulation Therapy: Role of Lead Positioning and Not of Total Electrical Energy Delivered. Journal of Personalized Medicine. 12. PMID 36294782 DOI: 10.3390/jpm12101643 |
0.627 |
|
| 2022 |
Iasevoli F, D'Ambrosio L, Ciccarelli M, Barone A, Gaudieri V, Cocozza S, Pontillo G, Brunetti A, Cuocolo A, de Bartolomeis A, Pappatà S. Altered Patterns of Brain Glucose Metabolism Involve More Extensive and Discrete Cortical Areas in Treatment-resistant Schizophrenia Patients Compared to Responder Patients and Controls: Results From a Head-to-Head 2-[18F]-FDG-PET Study. Schizophrenia Bulletin. PMID 36268829 DOI: 10.1093/schbul/sbac147 |
0.806 |
|
| 2022 |
de Bartolomeis A, Barone A, Vellucci L, Mazza B, Austin MC, Iasevoli F, Ciccarelli M. Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review. Molecular Neurobiology. PMID 35963926 DOI: 10.1007/s12035-022-02976-3 |
0.836 |
|
| 2022 |
Oliva V, De Prisco M, Pons-Cabrera MT, Guzmán P, Anmella G, Hidalgo-Mazzei D, Grande I, Fanelli G, Fabbri C, Serretti A, Fornaro M, Iasevoli F, de Bartolomeis A, Murru A, Vieta E, et al. Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder. Journal of Clinical Medicine. 11. PMID 35887699 DOI: 10.3390/jcm11143935 |
0.634 |
|
| 2022 |
de Bartolomeis A, Vellucci L, Barone A, Manchia M, De Luca V, Iasevoli F, Correll CU. Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. Pharmacology & Therapeutics. 108236. PMID 35764175 DOI: 10.1016/j.pharmthera.2022.108236 |
0.832 |
|
| 2022 |
Barone A, Billeci M, D'Amore S, De Prisco M, De Simone G, Ermini E, Freda V, Iannotta F, Luciani A, Pistone L, Rifici LM, Saia VM, Spennato G, Subosco F, Vellucci L, ... ... Iasevoli F, et al. The effects of sustained COVID-19 emergency and restrictions on the mental health of subjects with serious mental illness: A prospective study. Journal of Community Psychology. PMID 35615854 DOI: 10.1002/jcop.22886 |
0.779 |
|
| 2022 |
D'Urso G, Magliacano A, Rotbei S, Iasevoli F, de Bartolomeis A, Botta A. Predicting the Severity of Lockdown-Induced Psychiatric Symptoms with Machine Learning. Diagnostics (Basel, Switzerland). 12. PMID 35454005 DOI: 10.3390/diagnostics12040957 |
0.652 |
|
| 2022 |
de Bartolomeis A, Barone A, Buonaguro EF, Tomasetti C, Vellucci L, Iasevoli F. The Homer1 family of proteins at the crossroad of dopamine-glutamate signaling: An emerging molecular "Lego" in the pathophysiology of psychiatric disorders. A systematic review and translational insight. Neuroscience and Biobehavioral Reviews. 136: 104596. PMID 35248676 DOI: 10.1016/j.neubiorev.2022.104596 |
0.807 |
|
| 2022 |
Matrone M, Kotzalidis GD, Romano A, Bozzao A, Cuomo I, Valente F, Gabaglio C, Lombardozzi G, Trovini G, Amici E, Perrini F, De Persis S, Iasevoli F, De Filippis S, de Bartolomeis A. Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 114: 110493. PMID 34883221 DOI: 10.1016/j.pnpbp.2021.110493 |
0.693 |
|
| 2021 |
D'Urso G, Toscano E, Sanges V, Sauvaget A, Sheffer CE, Riccio MP, Ferrucci R, Iasevoli F, Priori A, Bravaccio C, de Bartolomeis A. Cerebellar Transcranial Direct Current Stimulation in Children with Autism Spectrum Disorder: A Pilot Study on Efficacy, Feasibility, Safety, and Unexpected Outcomes in Tic Disorder and Epilepsy. Journal of Clinical Medicine. 11. PMID 35011884 DOI: 10.3390/jcm11010143 |
0.656 |
|
| 2021 |
Fornaro M, Carvalho AF, De Prisco M, Mondin AM, Billeci M, Selby P, Iasevoli F, Berk M, Castle DJ, de Bartolomeis A. The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews. 132: 289-303. PMID 34838527 DOI: 10.1016/j.neubiorev.2021.11.039 |
0.667 |
|
| 2021 |
Fornaro M, Trinchillo A, Saccà F, Iasevoli F, Nolano M, de Bartolomeis A. Pharmacotherapy to prevent the onset of depression following traumatic brain injury. Expert Opinion On Pharmacotherapy. 1-8. PMID 34530652 DOI: 10.1080/14656566.2021.1980537 |
0.62 |
|
| 2021 |
Iasevoli F, Razzino E, Altavilla B, Avagliano C, Barone A, Ciccarelli M, D'Ambrosio L, Matrone M, Milandri F, Notar Francesco D, Fornaro M, de Bartolomeis A. Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia. Early Intervention in Psychiatry. PMID 33998142 DOI: 10.1111/eip.13174 |
0.811 |
|
| 2021 |
Barone A, Signoriello S, Latte G, Vellucci L, Giordano G, Avagliano C, Buonaguro EF, Marmo F, Tomasetti C, Iasevoli F, de Bartolomeis A. Modulation of glutamatergic functional connectivity by a prototypical antipsychotic: translational inference from a postsynaptic density Immediate-Early Gene-based network analysis. Behavioural Brain Research. 113160. PMID 33577880 DOI: 10.1016/j.bbr.2021.113160 |
0.807 |
|
| 2021 |
Berardis D, Rapini G, Olivieri L, Giardini A, Lauretis I, Serroni N, Orsolini L, Fornaro M, Iasevoli F, Trotta S, Cottura P, Vellante F, Alessandrini M, Giannantonio MD. Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases. Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology. 19: 174-178. PMID 33508803 DOI: 10.9758/cpn.2021.19.1.174 |
0.331 |
|
| 2020 |
Iasevoli F, Barone A, Buonaguro EF, Vellucci L, de Bartolomeis A. Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review. Expert Opinion On Drug Safety. PMID 32892632 DOI: 10.1080/14740338.2020.1820985 |
0.792 |
|
| 2020 |
Iasevoli F, Buonaguro EF, Avagliano C, Barone A, Eramo A, Vellucci L, de Bartolomeis A. The Effects of Antipsychotics on the Synaptic Plasticity Gene Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted. International Journal of Molecular Sciences. 21. PMID 32756473 DOI: 10.3390/Ijms21155555 |
0.807 |
|
| 2020 |
Fornaro M, Fusco A, Novello S, Mosca P, Anastasia A, De Blasio A, Iasevoli F, de Bartolomeis A. Predictors of Treatment Resistance Across Different Clinical Subtypes of Depression: Comparison of Unipolar vs. Bipolar Cases. Frontiers in Psychiatry. 11: 438. PMID 32670098 DOI: 10.3389/Fpsyt.2020.00438 |
0.664 |
|
| 2020 |
de Bartolomeis A, Manchia M, Marmo F, Vellucci L, Iasevoli F, Barone A. Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia. Frontiers in Psychiatry. 11: 369. PMID 32477178 DOI: 10.3389/Fpsyt.2020.00369 |
0.826 |
|
| 2020 |
Iasevoli F, Fornaro M, D'Urso G, Galletta D, Casella C, Paternoster M, Buccelli C, de Bartolomeis A. Psychological distress in patients with serious mental illness during the COVID-19 outbreak and one-month mass quarantine in Italy. Psychological Medicine. 1-3. PMID 32423496 DOI: 10.1017/S0033291720001841 |
0.627 |
|
| 2020 |
De Berardis D, Fornaro M, Anastasia A, Vellante F, Olivieri L, Rapini G, Serroni N, Orsolini L, Valchera A, Carano A, Tomasetti C, Ventriglio A, Bustini M, Pompili M, Serafini G, ... ... Iasevoli F, et al. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). PMID 32159712 DOI: 10.1590/1516-4446-2019-0690 |
0.673 |
|
| 2020 |
Vellucci L, Iasevoli F, Filomena Buonaguro E, Latte G, Tomasetti C, Marmo F, Avagliano C, Barone A, de Bartolomeis A. S205. A TRANSLATIONAL HOMER 1A-BASED NETWORK APPROACH: IMAGING HOW HALOPERIDOL MODULATES GLUTAMATE SYSTEM FUNCTIONAL CONNECTIVITY Schizophrenia Bulletin. 46: S116-S117. DOI: 10.1093/Schbul/Sbaa031.271 |
0.693 |
|
| 2020 |
Barone A, Iasevoli F, Avagliano C, D’Ambrosio L, Ciccarelli M, Matrone M, Notar Francesco D, Razzino E, Altavilla B, Milandri F, Pariano R, Vellucci L, de Bartolomeis A. S202. PROXIMAL AND DISTAL FACTORS ASSOCIATED WITH CLOZAPINE EXPOSURE IN A SAMPLE OF TREATMENT RESISTANT AND TREATMENT RESPONSIVE SCHIZOPHRENIA PATIENTS Schizophrenia Bulletin. 46: S115-S115. DOI: 10.1093/Schbul/Sbaa031.268 |
0.405 |
|
| 2020 |
Barone A, Iasevoli F, Matrone M, Filomena Buonaguro E, Falco M, Genesio R, Pignataro P, Capasso M, Gambale A, Avagliano C, Razzino E, Notar Francesco D, Ciccarelli M, Vitiello G, Andolfo I, et al. M170. GENETIC CHARACTERIZATION OF A COHORT OF PATIENTS AFFECTED BY SCHIZOPHRENIA. THE ROLE FOR RARE STRUCTURAL VARIANTS IN MODULATING TREATMENT RESISTANT ENDOPHENOTYPES: PRELIMINARY DATA Schizophrenia Bulletin. 46: S201-S201. DOI: 10.1093/Schbul/Sbaa030.482 |
0.344 |
|
| 2020 |
Iasevoli F, Cocozza S, D’Ambrosio L, Ciccarelli M, Barone A, Notar Francesco D, Pontillo G, Brunetti A, Cuocolo A, Pappatà S, de Bartolomeis A. M139. DIFFERENTIAL PATTERNS OF BRAIN METABOLISM IN STABILIZED, ACTIVELY SYMPTOMATIC TREATMENT RESISTANT VS. TREATMENT RESPONDER SCHIZOPHRENIA PATIENTS: A STUDY BY 18F-FDG-POSITRON EMISSION TOMOGRAPHY AND STRUCTURAL 3T MRI Schizophrenia Bulletin. 46: S188-S188. DOI: 10.1093/Schbul/Sbaa030.451 |
0.389 |
|
| 2020 |
Iasevoli F, Razzino E, Altavilla B, Avagliano C, Barone A, Ciccarelli M, D’Ambrosio L, Matrone M, Milandri F, Notar Francesco D, Pariano R, Vellucci L, de Bartolomeis A. O9.4. RELATIONSHIPS BETWEEN AGE AT ONSET OF PSYCHOTIC SYMPTOMS AND POOR RESPONSE TO ANTIPSYCHOTICS IN A SAMPLE OF TRS/NON-TRS PATIENTS Schizophrenia Bulletin. 46: S22-S22. DOI: 10.1093/Schbul/Sbaa028.051 |
0.386 |
|
| 2019 |
Iasevoli F, De Luca V, Nucifora FC. Editorial: Neurobiology, Clinical Course, and Therapeutic Approaches of Treatment-Resistant Schizophrenia: Toward an Integrated View. Frontiers in Psychiatry. 10: 870. PMID 31824360 DOI: 10.3389/Fpsyt.2019.00870 |
0.39 |
|
| 2019 |
de Bartolomeis A, Avagliano C, Vellucci L, D'Ambrosio L, Manchia M, D'Urso G, Buonaguro EF, Iasevoli F. Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia. Neuroscience and Biobehavioral Reviews. PMID 31461641 DOI: 10.1016/J.Neubiorev.2019.08.019 |
0.83 |
|
| 2019 |
Buonaguro EF, Morley-Fletcher S, Avagliano C, Vellucci L, Iasevoli F, Bouwalerh H, Van Camp G, Nicoletti F, Maccari S, de Bartolomeis A. Glutamatergic postsynaptic density in early life stress programming: Topographic gene expression of mGlu5 receptors and Homer proteins. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109725. PMID 31404590 DOI: 10.1016/J.Pnpbp.2019.109725 |
0.794 |
|
| 2019 |
Avagliano C, Iasevoli F, Buonaguro E, Vellucci L, De Bartolomeis A. Duration of antipsychotic treatment and doses/receptor profile modulate early gene expression throughout rat brain regions European Neuropsychopharmacology. 29: S610-S611. DOI: 10.1016/J.Euroneuro.2018.11.899 |
0.697 |
|
| 2018 |
Iasevoli F, Avagliano C, Altavilla B, Barone A, D'Ambrosio L, Matrone M, Notar Francesco D, Razzino E, de Bartolomeis A. Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs. Frontiers in Psychiatry. 9: 553. PMID 30429802 DOI: 10.3389/Fpsyt.2018.00553 |
0.805 |
|
| 2018 |
Iasevoli F, Avagliano C, Altavilla B, Barone A, Ciccarelli M, D'Ambrosio L, Notar Francesco D, Razzino E, Fornaro M, de Bartolomeis A. Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses. Psychiatry Research. 269: 481-493. PMID 30195742 DOI: 10.1016/J.Psychres.2018.08.109 |
0.809 |
|
| 2018 |
Iasevoli F, D'Ambrosio L, Notar Francesco D, Razzino E, Buonaguro EF, Giordano S, Patterson TL, de Bartolomeis A. Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients. Schizophrenia Research. PMID 29934250 DOI: 10.1016/J.Schres.2018.06.030 |
0.8 |
|
| 2018 |
Fornaro M, Anastasia A, Monaco F, Novello S, Fusco A, Iasevoli F, De Berardis D, Veronese N, Solmi M, de Bartolomeis A. Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants. Journal of Affective Disorders. 234: 131-138. PMID 29525354 DOI: 10.1016/J.Jad.2018.02.085 |
0.677 |
|
| 2018 |
de Bartolomeis A, Iasevoli F, Marmo F, Buonaguro EF, Avvisati L, Latte G, Tomasetti C. Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 29475793 DOI: 10.1016/J.Euroneuro.2018.01.006 |
0.804 |
|
| 2018 |
Iasevoli F, Avagliano C, Altavilla B, Barone A, Ciccarelli M, D’Ambrosio L, Francesco DN, Razzino E, de Bartolomeis A. S228. TOWARD EARLY DETECTION OF TREATMENT RESISTANT SCHIZOPHRENIA: PREDICTIVE INFORMATION ON NON-RESPONSE TO ANTIPSYCHOTICS BY EVALUATION OF A FEW CLINICAL FACTORS: A STUDY BY ROC CURVE ANALYSIS AND CONFIRMATORY MULTIVARIATE ANALYSIS Schizophrenia Bulletin. 44: S414-S415. DOI: 10.1093/Schbul/Sby018.1015 |
0.381 |
|
| 2018 |
Camilla A, Buonaguro E, Tomasetti C, Marmo F, Vellucci L, Iasevoli F, de Bartolomeis A. F234. TYPICAL AND ATYPICAL ANTIPSYCHOTICS’ D2R AFFINITY AND DOSES INFLUENCES POSTSYNAPTIC DENSITY BY MODULATING THE SPATIAL EXPRESSION OF HOMER1A A GENE HIGHLY IMPLICATED IN SYNAPTIC PLASTICITY AND PSYCHOSIS Schizophrenia Bulletin. 44: S313-S313. DOI: 10.1093/Schbul/Sby017.765 |
0.658 |
|
| 2018 |
Iasevoli F, Altavilla B, Avagliano C, Barone A, D’Ambrosio L, Matrone M, Francesco DN, Razzino E, de Bartolomeis A. F233. NEGATIVE SYMPTOMS ARE INDEPENDENT MODERATOR FACTORS OF TREATMENT RESISTANT SCHIZOPHRENIA EFFECTS ON MULTIPLE CLINICAL, PSYCHOPATHOLOGICAL, COGNITIVE AND PSYCHOSOCIAL VARIABLES Schizophrenia Bulletin. 44: S312-S313. DOI: 10.1093/Schbul/Sby017.764 |
0.352 |
|
| 2018 |
Iasevoli F, D’Ambrosio L, Francesco DN, Razzino E, Avagliano C, Buonaguro EF, Patterson T, de Bartolomeis A. T226. CLINICAL PREDICTORS OF FUNCTIONAL CAPACITY IN TREATMENT RESISTANT SCHIZOPHRENIA PATIENTS: COMPARISON WITH RESPONDER PATIENTS, ROLE OF NEGATIVE SYMPTOMS, PROBLEM SOLVING DYSFUNCTIONS, AND NEUROLOGICAL SOFT SIGNS Schizophrenia Bulletin. 44: S204-S204. DOI: 10.1093/Schbul/Sby016.502 |
0.382 |
|
| 2017 |
de Bartolomeis A, Buonaguro EF, Latte G, Rossi R, Marmo F, Iasevoli F, Tomasetti C. Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes. Frontiers in Behavioral Neuroscience. 11: 240. PMID 29321734 DOI: 10.3389/Fnbeh.2017.00240 |
0.82 |
|
| 2017 |
Fornaro M, Iasevoli F, Novello S, Fusco A, Anastasia A, De Berardis D, Valchera A, de Bartolomeis A. Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients. Journal of Affective Disorders. 228: 118-124. PMID 29245092 DOI: 10.1016/J.Jad.2017.12.009 |
0.309 |
|
| 2017 |
Bernardo P, Galletta D, Iasevoli F, D'Ambrosio L, Troisi S, Gennaro E, Zara F, Striano S, de Bartolomeis A, Coppola A. CHD2 mutations: Only epilepsy? Description of cognitive and behavioral profile in a case with a new mutation. Seizure. 51: 186-189. PMID 28910737 DOI: 10.1016/J.Seizure.2017.09.001 |
0.616 |
|
| 2017 |
de Bartolomeis A, Prinzivalli E, Callovini G, D'Ambrosio L, Altavilla B, Avagliano C, Iasevoli F. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28887181 DOI: 10.1016/J.Pnpbp.2017.09.002 |
0.711 |
|
| 2017 |
Vellante F, Sarchione F, Ebisch SJH, Salone A, Orsolini L, Marini S, Valchera A, Fornaro M, Carano A, Iasevoli F, Martinotti G, Di Giannantonio M, De Berardis D. Creativity and psychiatric illness: A functional perspective beyond chaos. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28689007 DOI: 10.1016/J.Pnpbp.2017.06.038 |
0.305 |
|
| 2017 |
Fornaro M, De Berardis D, Perna G, Solmi M, Veronese N, Orsolini L, Buonaguro EF, Iasevoli F, Köhler CA, Carvalho AF, de Bartolomeis A. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. Biomed Research International. 2017: 3084859. PMID 28573138 DOI: 10.1155/2017/3084859 |
0.78 |
|
| 2017 |
Mereu M, Contarini G, Buonaguro EF, Latte G, Managò F, Iasevoli F, de Bartolomeis A, Papaleo F. Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder. Neuropharmacology. 121: 179-194. PMID 28454982 DOI: 10.1016/J.Neuropharm.2017.04.037 |
0.404 |
|
| 2017 |
Tosato S, Albert U, Tomassi S, Iasevoli F, Carmassi C, Ferrari S, Nanni MG, Nivoli A, Volpe U, Atti AR, Fiorillo A. A Systematized Review of Atypical Antipsychotics in Pregnant Women: Balancing Between Risks of Untreated Illness and Risks of Drug-Related Adverse Effects. The Journal of Clinical Psychiatry. PMID 28297592 DOI: 10.4088/Jcp.15R10483 |
0.353 |
|
| 2017 |
Buonaguro EF, Iasevoli F, Marmo F, Eramo A, Latte G, Avagliano C, Tomasetti C, de Bartolomeis A. Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28235555 DOI: 10.1016/J.Pnpbp.2017.02.012 |
0.811 |
|
| 2017 |
de Berardis D, Fornaro M, Orsolini L, Iasevoli F, Tomasetti C, de Bartolomeis A, Serroni N, Valchera A, Carano A, Vellante F, Marini S, Piersanti M, Perna G, Martinotti G, Di Giannantonio M. The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. International Journal of Molecular Sciences. 18. PMID 28208695 DOI: 10.3390/Ijms18020349 |
0.811 |
|
| 2017 |
Iasevoli F, Fagiolini A, Formato MV, Prinzivalli E, Giordano S, Balletta R, De Luca V, de Bartolomeis A. Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients. Psychiatry Research. 249: 159-166. PMID 28104562 DOI: 10.1016/J.Psychres.2017.01.015 |
0.712 |
|
| 2017 |
Tomasetti C, Iasevoli F, Buonaguro EF, De Berardis D, Fornaro M, Fiengo AL, Martinotti G, Orsolini L, Valchera A, Di Giannantonio M, de Bartolomeis A. Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. International Journal of Molecular Sciences. 18. PMID 28085108 DOI: 10.3390/Ijms18010135 |
0.822 |
|
| 2017 |
D’Ambrosio L, Prinzivalli E, Oliviero N, Balletta R, Callovini G, Benedetta A, Formato M, Lattanzio S, Razzino E, Avagliano C, Iasevoli F, de Bartolomeis A. Impact of an Intervention of Neuro-cognitive Rehabilitation in Treatment Resistant Schizophrenia (TRS) Compared to Schizophrenia Responder Patients European Psychiatry. 41: S266-S267. DOI: 10.1016/J.Eurpsy.2017.02.085 |
0.391 |
|
| 2016 |
Fornaro M, Stubbs B, De Berardis D, Iasevoli F, Solmi M, Veronese N, Carano A, Perna G, De Bartolomeis A. Does the "" Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients. Clinical Practice and Epidemiology in Mental Health : Cp & Emh. 12: 142-157. PMID 28217142 DOI: 10.2174/1745017901612010142 |
0.312 |
|
| 2016 |
Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo AL, Martinotti G, Vellante F, Matarazzo I, Vecchiotti R, Perna G, Di Nicola M, Carano A, de Bartolomeis A, et al. Current and future perspectives on the Major Depressive Disorder: Focus on the new multimodal antidepressant Vortioxetine. Cns & Neurological Disorders Drug Targets. PMID 27781949 DOI: 10.2174/1871527315666161025140111 |
0.793 |
|
| 2016 |
De Berardis D, Fornaro M, Orsolini L, Iasevoli F, Tomasetti C, de Bartolomeis A, Serroni N, De Lauretis I, Girinelli G, Mazza M, Valchera A, Carano A, Vellante F, Matarazzo I, Perna G, et al. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice. Cns Spectrums. 1-6. PMID 27702411 DOI: 10.1017/S1092852916000572 |
0.784 |
|
| 2016 |
Orsolini L, Valchera A, Vecchiotti R, Tomasetti C, Iasevoli F, Fornaro M, De Berardis D, Perna G, Pompili M, Bellantuono C. Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates. Frontiers in Psychiatry. 7: 138. PMID 27570512 DOI: 10.3389/Fpsyt.2016.00138 |
0.652 |
|
| 2016 |
Buonaguro EF, Tomasetti C, Chiodini P, Marmo F, Latte G, Rossi R, Avvisati L, Iasevoli F, de Bartolomeis A. Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia. Journal of Psychopharmacology (Oxford, England). PMID 27443599 DOI: 10.1177/0269881116658987 |
0.826 |
|
| 2016 |
De Berardis D, Orsolini L, Iasevoli F, Prinzivalli E, de Bartolomeis A, Serroni N, Mazza M, Valchera A, Fornaro M, Vecchiotti R, Carano A, Sepede G, Vellante F, Matarazzo I, Pompili M, et al. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. Current Pharmaceutical Design. PMID 27396597 DOI: 10.1016/J.Eurpsy.2016.01.563 |
0.739 |
|
| 2016 |
Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo A, Martinotti G, Mazza M, Perna G, Carano A, de Bartolomeis A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opinion On Drug Safety. PMID 27347638 DOI: 10.1080/14740338.2016.1201475 |
0.321 |
|
| 2016 |
de Bartolomeis A, Marmo F, Buonaguro EF, Latte G, Tomasetti C, Iasevoli F. Switching antipsychotics: imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 27177972 DOI: 10.1016/J.Pnpbp.2016.04.015 |
0.815 |
|
| 2016 |
Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Bonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant Vortioxetine. Expert Review of Neurotherapeutics. PMID 27050932 DOI: 10.1586/14737175.2016.1173545 |
0.785 |
|
| 2016 |
Salone A, Di Giacinto A, Lai C, De Berardis D, Iasevoli F, Fornaro M, De Risio L, Santacroce R, Martinotti G, Giannantonio MD. The Interface between Neuroscience and Neuro-Psychoanalysis: Focus on Brain Connectivity. Frontiers in Human Neuroscience. 10: 20. PMID 26869904 DOI: 10.3389/Fnhum.2016.00020 |
0.375 |
|
| 2016 |
Buonaguro E, Latte G, Avvisati L, Marmo F, Iasevoli F, Tomasetti C, De Bartolomeis A. P.1.009 Effects of caffeine, nicotine and their combination with haloperidol on PSD molecules: relevance to psychiatric diseases European Neuropsychopharmacology. 26: S10-S11. DOI: 10.1016/S0924-977X(16)70012-5 |
0.752 |
|
| 2016 |
Buonaguro E, Iasevoli F, Latte G, Avagliano C, Vellucci L, Marmo F, Tomasetti C, De Bartolomeis A. Analysis of Homer1a expression levels as a tool to investigate antipsychotic-related perturbation of synaptic plasticity: translational implications for schizophrenia treatment strategies European Neuropsychopharmacology. 26: S233. DOI: 10.1016/S0924-977X(16)31095-1 |
0.81 |
|
| 2016 |
Latte G, Iasevoli F, Buonaguro E, Tomasetti C, Marmo F, Avagliano C, Vellucci L, De Bartolomeis A. Haloperidol modulates functional connectivity in the glutamate system: a postsynaptic density immediate-early gene-based network approach European Neuropsychopharmacology. 26: S224-S225. DOI: 10.1016/S0924-977X(16)31081-1 |
0.773 |
|
| 2015 |
de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. Cns Drugs. 29: 773-99. PMID 26346901 DOI: 10.1007/S40263-015-0278-3 |
0.819 |
|
| 2015 |
Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E, De Berardis D, Tomasetti C, de Bartolomeis A. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 65: 34-48. PMID 26320028 DOI: 10.1016/J.Pnpbp.2015.08.010 |
0.8 |
|
| 2015 |
De Berardis D, Orsolini L, Serroni N, Girinelli G, Iasevoli F, Tomasetti C, de Bartolomeis A, Mazza M, Valchera A, Fornaro M, Perna G, Piersanti M, Di Nicola M, Cavuto M, Martinotti G, et al. A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder. Cns & Neurological Disorders Drug Targets. PMID 26295824 DOI: 10.2174/1871527314666150821103825 |
0.775 |
|
| 2015 |
Serchov T, Clement HW, Schwarz MK, Iasevoli F, Tosh DK, Idzko M, Jacobson KA, de Bartolomeis A, Normann C, Biber K, van Calker D. Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a. Neuron. 87: 549-62. PMID 26247862 DOI: 10.1016/J.Neuron.2015.07.010 |
0.677 |
|
| 2015 |
de Bartolomeis A, Errico F, Aceto G, Tomasetti C, Usiello A, Iasevoli F. D-aspartate dysregulation in Ddo(-/-) mice modulates phencyclidine-induced gene expression changes of postsynaptic density molecules in cortex and striatum. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 62: 35-43. PMID 25979765 DOI: 10.1016/J.Pnpbp.2015.05.003 |
0.811 |
|
| 2015 |
De Berardis D, Marini S, Serroni N, Iasevoli F, Tomasetti C, de Bartolomeis A, Mazza M, Tempesta D, Valchera A, Fornaro M, Pompili M, Sepede G, Vellante F, Orsolini L, Martinotti G, et al. Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials. Current Drug Targets. 16: 1094-106. PMID 25944011 DOI: 10.2174/1389450116666150506114108 |
0.78 |
|
| 2015 |
Pivonello R, Simeoli C, De Martino MC, Cozzolino A, De Leo M, Iacuaniello D, Pivonello C, Negri M, Pellecchia MT, Iasevoli F, Colao A. Neuropsychiatric disorders in Cushing's syndrome. Frontiers in Neuroscience. 9: 129. PMID 25941467 DOI: 10.3389/Fnins.2015.00129 |
0.327 |
|
| 2015 |
Fornaro M, De Berardis D, Mazza M, Pino M, Favaretto E, Bedani F, Wieser C, Indelicato L, Paternò VF, Lo Monaco F, Dugo F, Ventriglio A, Mungo S, Selle V, Valchera A, ... ... Iasevoli F, et al. Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). Journal of Affective Disorders. 178: 112-20. PMID 25805403 DOI: 10.1016/J.Jad.2015.03.001 |
0.767 |
|
| 2015 |
Errico F, D'Argenio V, Sforazzini F, Iasevoli F, Squillace M, Guerri G, Napolitano F, Angrisano T, Di Maio A, Keller S, Vitucci D, Galbusera A, Chiariotti L, Bertolino A, de Bartolomeis A, et al. A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Translational Psychiatry. 5: e512. PMID 25689573 DOI: 10.1016/S0924-9338(15)31301-8 |
0.724 |
|
| 2015 |
de Bartolomeis A, Iasevoli F, Marmo F, Buonaguro EF, Eramo A, Rossi R, Avvisati L, Latte G, Tomasetti C. Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 566-82. PMID 25649681 DOI: 10.1016/J.Euroneuro.2015.01.003 |
0.813 |
|
| 2015 |
De Berardis D, Serroni N, Campanella D, Rapini G, Olivieri L, Feliziani B, Carano A, Valchera A, Iasevoli F, Tomasetti C, Mazza M, Fornaro M, Perna G, Di Nicola M, Martinotti G, et al. Alexithymia, responsibility attitudes and suicide ideation among outpatients with obsessive-compulsive disorder: an exploratory study. Comprehensive Psychiatry. 58: 82-7. PMID 25591904 DOI: 10.1016/J.Comppsych.2014.12.016 |
0.661 |
|
| 2015 |
De Berardis D, Fornaro M, Serroni N, Campanella D, Rapini G, Olivieri L, Srinivasan V, Iasevoli F, Tomasetti C, De Bartolomeis A, Valchera A, Perna G, Mazza M, Di Nicola M, Martinotti G, et al. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. International Journal of Molecular Sciences. 16: 1111-30. PMID 25569089 DOI: 10.3390/Ijms16011111 |
0.79 |
|
| 2015 |
Fornaro M, De Berardis D, De Pasquale C, Indelicato L, Pollice R, Valchera A, Perna G, Iasevoli F, Tomasetti C, Martinotti G, Koshy AS, Fasmer OB, Oedegaard KJ. Prevalence and clinical features associated to bipolar disorder-migraine comorbidity: a systematic review. Comprehensive Psychiatry. 56: 1-16. PMID 25306379 DOI: 10.1016/J.Comppsych.2014.09.020 |
0.663 |
|
| 2015 |
Iasevoli F, Giordano S, Balletta R, Avvisati L, Formato M, Prinzivalli E, Fico G, Avagliano C, Caiazzo M, Tomasetti C, De Bartolomeis A. Worse Comes to Worst in Schizophrenia: Treatment Resistant Schizophrenia Patients Show Greater Impairment in Functional Milestones of Everyday Living Compared to Other Psychiatric Disabling Conditions European Psychiatry. 30: 1754. DOI: 10.1016/S0924-9338(15)31349-3 |
0.394 |
|
| 2015 |
de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism Cns Drugs. DOI: 10.1007/s40263-015-0278-3 |
0.665 |
|
| 2014 |
de Bartolomeis A, Iasevoli F, Tomasetti C, Buonaguro EF. MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective. Molecular Neurobiology. PMID 25394379 DOI: 10.1007/S12035-014-8962-8 |
0.809 |
|
| 2014 |
Fornaro M, De Berardis D, Iasevoli F, Pistorio ML, D?Angelo E, Mungo S, Martino M, Ventriglio A, Cattaneo CI, Favaretto E, Del Debbio A, Romano A, Ciampa G, Elassy M, Perugi G, et al. Corrigendum to "Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and "therapeutic sensation seeking" in response towards subjective intolerance to pain" [J. Affect. Disord. 151 (2) (November 2013), 596-604]. Journal of Affective Disorders. 170: 22. PMID 25217760 DOI: 10.1016/J.Jad.2014.08.014 |
0.307 |
|
| 2014 |
Iasevoli F, Buonaguro EF, Sarappa C, Marmo F, Latte G, Rossi R, Eramo A, Tomasetti C, de Bartolomeis A. Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 54: 299-314. PMID 25025505 DOI: 10.1016/J.Pnpbp.2014.07.003 |
0.822 |
|
| 2014 |
De Berardis D, Campanella D, Serroni N, Rapini G, Olivieri L, Fornaro M, Valchera A, Iasevoli F, Napoletano C, Martinotti G, Giannantonio MD. Clozapine-related pericarditis during titration phase in a patient with resistant schizophrenia and concomitant valproate treatment: a case report. Journal of Clinical Psychopharmacology. 34: 649-51. PMID 25006818 DOI: 10.1097/Jcp.0000000000000179 |
0.374 |
|
| 2014 |
Iasevoli F, Tomasetti C, Buonaguro EF, de Bartolomeis A. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Current Neuropharmacology. 12: 219-38. PMID 24851087 DOI: 10.2174/1570159X12666140324183406 |
0.83 |
|
| 2014 |
Fornaro M, Martino M, Mattei C, Prestia D, Vinciguerra V, De Berardis D, De Pasquale C, Iasevoli F, Mungo S, Fornaro P. Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1269-78. PMID 24842649 DOI: 10.1016/J.Euroneuro.2014.04.004 |
0.327 |
|
| 2014 |
Iasevoli F, Buonaguro EF, Marconi M, Di Giovambattista E, Rapagnani MP, De Berardis D, Martinotti G, Mazza M, Balletta R, Serroni N, Di Giannantonio M, de Bartolomeis A, Valchera A. Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study. Isrn Pharmacology. 2014: 762127. PMID 24592333 DOI: 10.1155/2014/762127 |
0.791 |
|
| 2014 |
de Bartolomeis A, Buonaguro EF, Iasevoli F, Tomasetti C. The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment. Journal of Psychopharmacology (Oxford, England). 28: 505-526. PMID 24554693 DOI: 10.1177/0269881114523864 |
0.816 |
|
| 2014 |
De Berardis D, Serroni N, Marini S, Rapini G, Carano A, Valchera A, Iasevoli F, Mazza M, Signorelli M, Aguglia E, Perna G, Martinotti G, Varasano PA, Pressanti GL, Di Giannantonio M. Alexithymia, suicidal ideation, and serum lipid levels among drug-naïve outpatients with obsessive-compulsive disorder. Revista Brasileira De Psiquiatria (SãO Paulo, Brazil : 1999). 36: 125-30. PMID 24554275 DOI: 10.1590/1516-4446-2013-1189 |
0.31 |
|
| 2014 |
De Berardis D, Fornaro M, Serroni N, Marini S, Piersanti M, Cavuto M, Valchera A, Mazza M, Girinelli G, Iasevoli F, Perna G, Martinotti G, Di Giannantonio M. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Patents On Endocrine, Metabolic & Immune Drug Discovery. 8: 30-7. PMID 24372345 DOI: 10.2174/1872214807666131229125700 |
0.407 |
|
| 2014 |
de Bartolomeis A, Latte G, Tomasetti C, Iasevoli F. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Molecular Neurobiology. 49: 484-511. PMID 23999870 DOI: 10.1007/S12035-013-8534-3 |
0.828 |
|
| 2014 |
Marmo F, Buonaguro E, Latte G, Iasevoli F, De Bartolomeis A. P.3.c.008 Immediate early and constitutive genes expression in antipsychotic switching paradigm: from clinical practice to animal model European Neuropsychopharmacology. 24: S519. DOI: 10.1016/S0924-977X(14)70831-4 |
0.767 |
|
| 2014 |
Avvisati L, Latte G, Gilardi V, Giordano S, Balletta R, Prinzivalli E, Buonaguro E, Elce C, Rossi R, Formato M, Acampora R, Avagliano C, Fico G, Mazzola G, Tomasetti C, ... ... Iasevoli F, et al. EPA-1118 - Knowledge of the illness and its relations with quality of life, social functioning, cognitive performances, and adherence in psychotic patients: Toward effectiveness-focused interventions European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78387-7 |
0.31 |
|
| 2014 |
Balletta R, Cucciniello C, Formato M, Pecoraro G, Orlando S, Mazzola G, Avagliano C, Fico G, Bartolomeis AD, Micanti F, Iasevoli F. EPA-1116 - Obesity affects cognitive performances even in the absence of obvious psychopathological alterations. a comparison with schizophrenia subjects and non-affected controls European Psychiatry. 29: 1. DOI: 10.1016/S0924-9338(14)78386-5 |
0.313 |
|
| 2014 |
Iasevoli F, Tomasetti C, Buonaguro EF, Latte G, Rossi R, Avvisati L, Avagliano C, Fico G, Mazzola G, Marmo F, de Bartolomeis A. Poster #T100 MINOCYCLINE ADD-ON TO HALOPERIDOL BLUNTS HALOPERIDOL-MEDIATED EXPRESSION OF EARLY GENES IMPLICATED IN GLUTAMATERGIC NEUROTRANSMISSION IN BOTH VEHICLE AND KETAMINE-TREATED RATS Schizophrenia Research. 153: S325. DOI: 10.1016/S0920-9964(14)70917-X |
0.772 |
|
| 2014 |
Iasevoli F, Giordano S, Balletta R, Buonaguro EF, Tomasetti C, Rossi R, Gilardi V, Cucciniello C, Elce C, Acampora R, de Bartolomeis A. Poster #M252 PATIENTS' OPINIONS ON KEY ISSUES OF PSYCHOSOCIAL FUNCTIONING AMONG NON-PSYCHOTICS PSYCHOTIC RESPONDERS AND NON-RESPONDERS: CORRELATION WITH CLINICAL VARIABLES AND SYMPTOM DOMAINS RELEVANT TO REMISSION FROM PSYCHOSIS Schizophrenia Research. 153: S281. DOI: 10.1016/S0920-9964(14)70802-3 |
0.666 |
|
| 2014 |
Iasevoli F, Giordano S, Balletta R, Avvisati L, Latte G, Gilardi V, Buonaguro EF, Formato M, Prinzivalli E, Rossi R, de Bartolomeis A. Poster #S257 TOUCHING BY HAND HOW PSYCHOTIC FEATURES TRANSLATE INTO WORSE LIFE CONDITIONS: THE RELATION OF KEY PSYCHOSOCIAL ISSUES WITH CLINICAL VARIABLES IN NON-PSYCHOTIC, PSYCHOTIC RESPONDER, AND PSYCHOTIC NON-RESPONDER PATIENTS Schizophrenia Research. 153: S183. DOI: 10.1016/S0920-9964(14)70536-5 |
0.659 |
|
| 2013 |
Iasevoli F, Balletta R, Gilardi V, Giordano S, de Bartolomeis A. Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment. Neuropsychiatric Disease and Treatment. 9: 1113-20. PMID 23950651 DOI: 10.2147/NDT.S47571 |
0.652 |
|
| 2013 |
de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Research. 210: 387-95. PMID 23910239 DOI: 10.1016/J.Psychres.2013.06.042 |
0.816 |
|
| 2013 |
Fornaro M, De Berardis D, Iasevoli F, Pistorio ML, D'Angelo E, Mungo S, Martino M, Ventriglio A, Cattaneo CI, Favaretto E, Del Debbio A, Romano A, Ciampa G, Elassy M, Perugi G, et al. Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: relationship with cyclothymic temperament and "therapeutic sensation seeking" in response towards subjective intolerance to pain. Journal of Affective Disorders. 151: 596-604. PMID 23906864 DOI: 10.1016/J.Jad.2013.07.004 |
0.328 |
|
| 2013 |
Iasevoli F, Aloj L, Latte G, Avvisati L, Marmo F, Tomasetti C, Buonaguro EF, Simeoli C, Pivonello R, Colao A, de Bartolomeis A. The glucocorticoid analog dexamethasone alters the expression and the distribution of dopamine receptors and enkephalin within cortico-subcortical regions. Current Molecular Pharmacology. 6: 149-55. PMID 23862670 DOI: 10.2174/187446720603140415215941 |
0.791 |
|
| 2013 |
Iasevoli F, Valchera A, Di Giovambattista E, Marconi M, Rapagnani MP, De Berardis D, Martinotti G, Fornaro M, Mazza M, Tomasetti C, Buonaguro EF, Di Giannantonio M, Perugi G, de Bartolomeis A. Affective temperaments are associated with specific clusters of symptoms and psychopathology: a cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or depressive relapse. Journal of Affective Disorders. 151: 540-50. PMID 23856282 DOI: 10.1016/J.Jad.2013.06.041 |
0.789 |
|
| 2013 |
de Bartolomeis A, Avvisati L, Iasevoli F, Tomasetti C. Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment. European Journal of Pharmacology. 718: 502-23. PMID 23834777 DOI: 10.1016/J.Ejphar.2013.06.034 |
0.812 |
|
| 2013 |
de Bartolomeis A, Sarappa C, Buonaguro EF, Marmo F, Eramo A, Tomasetti C, Iasevoli F. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 46: 1-12. PMID 23800465 DOI: 10.1016/J.Pnpbp.2013.06.010 |
0.824 |
|
| 2013 |
Martinotti G, Lupi M, Sarchione F, Santacroce R, Salone A, De Berardis D, Serroni N, Cavuto M, Signorelli M, Aguglia E, Valchera A, Iasevoli F, Di Giannantonio M. The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. Current Pharmaceutical Design. 19: 6367-74. PMID 23782139 DOI: 10.2174/13816128113199990425 |
0.325 |
|
| 2013 |
De Berardis D, Marini S, Serroni N, Rapini G, Iasevoli F, Valchera A, Signorelli M, Aguglia E, Perna G, Salone A, Di Iorio G, Martinotti G, Di Giannantonio M. S-Adenosyl-L-Methionine augmentation in patients with stage II treatment-resistant major depressive disorder: an open label, fixed dose, single-blind study. Thescientificworldjournal. 2013: 204649. PMID 23766680 DOI: 10.1155/2013/204649 |
0.333 |
|
| 2013 |
De Berardis D, Marini S, Fornaro M, Srinivasan V, Iasevoli F, Tomasetti C, Valchera A, Perna G, Quera-Salva MA, Martinotti G, di Giannantonio M. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. International Journal of Molecular Sciences. 14: 12458-83. PMID 23765220 DOI: 10.3390/Ijms140612458 |
0.683 |
|
| 2013 |
De Berardis D, Conti CM, Marini S, Ferri F, Iasevoli F, Valchera A, Fornaro M, Cavuto M, Srinivasan V, Perna G, Carano A, Piersanti M, Martinotti G, Di Giannantonio M. Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data. International Journal of Immunopathology and Pharmacology. 26: 299-304. PMID 23755745 DOI: 10.1177/039463201302600203 |
0.321 |
|
| 2013 |
De Berardis D, Marini S, Iasevoli F, Tomasetti C, de Bartolomeis A, Mazza M, Valchera A, Fornaro M, Cavuto M, Srinivasan V, Sepede G, Martinotti G, Di Giannantonio M. The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review. Cns & Neurological Disorders Drug Targets. 12: 252-64. PMID 23469841 DOI: 10.2174/1871527311312020012 |
0.806 |
|
| 2013 |
de Bartolomeis A, Marmo F, Buonaguro EF, Rossi R, Tomasetti C, Iasevoli F. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1516-29. PMID 23357084 DOI: 10.1016/J.Euroneuro.2012.11.014 |
0.817 |
|
| 2013 |
De Berardis D, Marini S, Carano A, Lang AP, Cavuto M, Piersanti M, Fornaro M, Perna G, Valchera A, Mazza M, Iasevoli F, Martinotti G, Di Giannantonio M. Efficacy and safety of long acting injectable atypical antipsychotics: a review. Current Clinical Pharmacology. 8: 256-64. PMID 23343445 DOI: 10.2174/15748847113089990056 |
0.42 |
|
| 2013 |
de Bartolomeis A, Buonaguro EF, Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology. 225: 1-19. PMID 23179966 DOI: 10.1007/S00213-012-2921-8 |
0.712 |
|
| 2013 |
Iasevoli F, Tomasetti C, de Bartolomeis A. Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases. Neurochemical Research. 38: 1-22. PMID 22991141 DOI: 10.1007/S11064-012-0886-Y |
0.781 |
|
| 2013 |
Iasevoli F, Avvisati L, Latte G, Buonaguro EF, Tomasetti C, Aloj L, De Bartolomeis A. Differential adaptive changes in dopaminergic system by acute vs. subchronic ketamine: Relevance for psychosis pathophysiology and treatment Current Signal Transduction Therapy. 8: 119-128. DOI: 10.2174/15743624113086660004 |
0.677 |
|
| 2013 |
De Berardis D, Conti CM, Marini S, Serroni N, Moschetta FS, Carano A, Valchera A, Iasevoli F, Fornaro M, Perna G, Di Iorio G, Martinotti G, Niolu C, Siracusano A, Di Giannantonio M. C-reactive protein level and its relationship with suicide risk and alexithymia among newly diagnosed, drug-naïve patients with non-affective psychosis European Journal of Inflammation. 11: 215-221. DOI: 10.1177/1721727X1301100120 |
0.321 |
|
| 2013 |
Buonaguro E, Marmo F, Sarappa C, Eramo A, Tomasetti C, Iasevoli F, De Bartolomeis A. P.1.g.054 Gene-expression imaging by N-methyl-D-aspartate receptor antagonists: implications for dopamine–glutamate interplay in psychosis European Neuropsychopharmacology. 23: S220-S221. DOI: 10.1016/S0924-977X(13)70341-9 |
0.788 |
|
| 2013 |
Avvisati L, Rossi R, Latte G, Buonaguro EF, Eramo A, Marmo F, Tomasetti C, Sarappa C, Iasevoli F, Bartolomeis Ad. 2251 – Cortical and subcortical gene-expression imaging by different n-methyl-daspartate receptor (nmda-r) antagonists at glutammatergic synapses: implications for dopamine-glutamate interplay in psychoses European Psychiatry. 28: 1. DOI: 10.1016/S0924-9338(13)77115-3 |
0.801 |
|
| 2012 |
Iasevoli F, Latte G, Avvisati L, Sarappa C, Aloj L, de Bartolomeis A. The expression of genes involved in glucose metabolism is affected by N-methyl-D-aspartate receptor antagonism: a putative link between metabolism and an animal model of psychosis. Journal of Neuroscience Research. 90: 1756-67. PMID 22605548 DOI: 10.1002/Jnr.23071 |
0.684 |
|
| 2012 |
de Bartolomeis A, Sarappa C, Magara S, Iasevoli F. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. European Journal of Pharmacology. 682: 1-11. PMID 22387855 DOI: 10.1016/J.Ejphar.2012.02.033 |
0.74 |
|
| 2012 |
Iasevoli F, Balletta R, Giordano S, Buonaguro E, Latte G, de Bartolomeis A. P.3.c.043 Resistance to antipsychotics is associated with higher cognitive impairment compared to non-resistant schizophrenia European Neuropsychopharmacology. 22: S341-S342. DOI: 10.1016/S0924-977X(12)70527-8 |
0.686 |
|
| 2012 |
Iasevoli F, Sarappa C, Eramo A, Bonaguro EF, Marmo F, Bartolomeis A. Poster #9 ANTAGONISTS AT N-METHYL-D-ASPARTATE RECEPTOR (NMDA-R) WITH DIFFERENT CLINICAL PROFILE AFFECT DIFFERENTLY THE TRANSCRIPTS OF CONSTITUTIVE AND INDUCIBLE EARLY GENES AT POSTSYNAPTIC DENSITY Schizophrenia Research. 136. DOI: 10.1016/S0920-9964(12)70581-9 |
0.771 |
|
| 2012 |
Iasevoli F, Latte G, Avvisati L, Tomasetti C, Rossi R, Aloj L, Bartolomeis A. Poster #110 USING A TRANSLATIONAL APPROACH TO STUDY BEHAVIORAL DISORDERS’ PATHOPHYSIOLOGY: DOPAMINE SYSTEM IS AFFECTED IN A GLUTAMATERGIC ANIMAL MODEL OF PSYCHOSIS Schizophrenia Research. 136. DOI: 10.1016/S0920-9964(12)70425-5 |
0.321 |
|
| 2011 |
Iasevoli F, Cicale M, Abbott LC, de Bartolomeis A. Striatal expression of Homer1a is affected by genotype but not dystonic phenotype of tottering mice: a model of spontaneously occurring motor disturbances. Neuroscience Letters. 503: 176-80. PMID 21884752 DOI: 10.1016/J.Neulet.2011.08.025 |
0.652 |
|
| 2011 |
Tomasetti C, Dell'Aversano C, Iasevoli F, Marmo F, de Bartolomeis A. The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 35: 184-97. PMID 21055435 DOI: 10.1016/J.Pnpbp.2010.10.025 |
0.82 |
|
| 2011 |
Iasevoli F, Ambesi-Impiombato A, Fiore G, Panariello F, Muscettola G, de Bartolomeis A. Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. Journal of Psychopharmacology (Oxford, England). 25: 875-87. PMID 20147574 DOI: 10.1177/0269881109358199 |
0.801 |
|
| 2011 |
Calandro S, Avvisati L, Latte G, Patrì A, Rossi R, Buonaguro E, Sarappa C, Iasevoli F, Aloj L, de Bartolomeis A. P.1.032 Where and when ketamine alters the dopamine system: translational implications for drug addiction and psychoses European Neuropsychopharmacology. 21: S26-S27. DOI: 10.1016/S0924-977X(11)70031-1 |
0.667 |
|
| 2011 |
Marmo F, Latte G, Avvisati L, Patrì A, Rossi R, Buonaguro E, Tomasetti C, Iasevoli F, Aloj L, de Bartolomeis A. P.1.031 Expression of glucose metabolism genes in a psychosis model: a molecular link between NMDA receptor hypofunction and metabolism disorders? European Neuropsychopharmacology. 21: S25-S26. DOI: 10.1016/S0924-977X(11)70030-X |
0.76 |
|
| 2011 |
Buonaguro EF, Marmo F, Avvisati L, Latte G, Rossi R, Patrì A, Sarappa C, Iasevoli F, Aloj L, Bartolomeis Ad. P03-62 - Opioidergic system and N-methyl D-aspartate receptor (NMDA-R) hypofunction: Translational implications for the pathophysiology of psychosis and drug addiction European Psychiatry. 26: 1231-1231. DOI: 10.1016/S0924-9338(11)72936-4 |
0.693 |
|
| 2010 |
Iasevoli F, Tomasetti C, Marmo F, Bravi D, Arnt J, de Bartolomeis A. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology. 212: 329-44. PMID 20652539 DOI: 10.1007/S00213-010-1954-0 |
0.831 |
|
| 2010 |
Iasevoli F, Fiore G, Cicale M, Muscettola G, de Bartolomeis A. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry Research. 177: 255-60. PMID 20304506 DOI: 10.1016/J.Psychres.2010.02.009 |
0.82 |
|
| 2009 |
Iasevoli F, Tomasetti C, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A. Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 33: 813-21. PMID 19243698 DOI: 10.1016/J.Pnpbp.2009.02.009 |
0.817 |
|
| 2009 |
Dell'aversano C, Tomasetti C, Iasevoli F, de Bartolomeis A. Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Research Bulletin. 79: 123-9. PMID 19189858 DOI: 10.1016/J.Brainresbull.2009.01.006 |
0.828 |
|
| 2008 |
Iasevoli F, Ambesi-Impiombato A, Fiore G, Panariello F, Muscettola G, de Bartolomeis A. P.1.17 Topographical and temporal distribution of Homer1a expression is correlated to antipsychotics dopaminergic profile European Neuropsychopharmacology. 18: s15-s16. DOI: 10.1016/S0924-977X(08)70018-X |
0.666 |
|
| 2007 |
Tomasetti C, Dell'Aversano C, Iasevoli F, de Bartolomeis A. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience. 150: 144-58. PMID 17916411 DOI: 10.1016/J.Neuroscience.2007.08.022 |
0.703 |
|
| 2007 |
Iasevoli F, Polese D, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A. Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis. Neuroscience Letters. 416: 1-5. PMID 17317002 DOI: 10.1016/J.Neulet.2007.01.041 |
0.819 |
|
| 2005 |
de Bartolomeis A, Fiore G, Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Current Pharmaceutical Design. 11: 3561-94. PMID 16248808 DOI: 10.2174/138161205774414538 |
0.733 |
|
| 2003 |
de Bartolomeis A, Iasevoli F. The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. Psychopharmacology Bulletin. 37: 51-83. PMID 14608240 |
0.663 |
|
| 2001 |
De Bartolomeis A, Polese D, Amato de Serpis A, Iasevoli F, Ambesi-Impiombato A, Galietta A, Muscettola G. NMDA receptor hypofunction: Cortical and subcortical CaMKII mRNA gene expression European Neuropsychopharmacology. 11: S290. DOI: 10.1016/S0924-977X(01)80381-3 |
0.779 |
|
| Show low-probability matches. |